Cutera stock trades at USD 0.008 after Nasdaq delisting

Published on 10/04/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cutera stock now trades over the counter after the company exited Nasdaq in 2025. Historical revenue fell from USD 212.4 million in 2023 to USD 138.5 million in 2024.

CUTR, US2321091082, Illustration mit AI erstellt.

Cutera (ISIN US2321091082) stock was quoted at USD 0.008 on OTC Markets on October 2, 2026, putting the post-bankruptcy security firmly in the over-the-counter market. The companys Nasdaq exit in March 2025 remains the defining structural change for the shares, according to Ground News.

OTC trading follows Nasdaq exit

The October 2 quote gives the stock a concrete market reference after Cutera moved away from its former Nasdaq listing. A September 21, 2026 company record identifies the security as CUTRQ, assigns ISIN US2321091082 and places Cutera in Health Care Equipment and Supplies, according to Eulerpool.

The listing change followed a prepackaged Chapter 11 filing in March 2025 and a debt restructuring that transferred essentially all equity to noteholders. AInvest reported that the restructuring eliminated more than USD 400 million of debt within 57 days.

Revenue decline sets the operating context

Historical revenue also shows the pressure that preceded the restructuring. Cutera revenue fell from USD 212.4 million in fiscal year 2023 to USD 138.5 million in fiscal year 2024, a decline of 34.8 percent, according to AInvest.

The comparison matters because the company sells capital-intensive aesthetic systems, while its operating model also included device placements in medical spas. AInvest reported that the third quarter of 2024 revenue was down 30 percent year over year, linking the decline to weaker demand for body-contouring devices.

Cutera stock remains an OTC security

For investors, the key distinction is between the former Nasdaq-listed company and the security now quoted on OTC Markets. The USD 0.008 reference price on October 2, 2026, therefore describes an OTC instrument rather than a Nasdaq listing, while the fiscal year 2024 revenue comparison frames the companys pre-restructuring operating contraction.